Cover Image
市場調查報告書

P-Selectin (CD62P) :開發中產品分析

P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363577
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
P-Selectin (CD62P) :開發中產品分析 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 52 Pages
簡介

本報告提供P-Selectin (CD62P)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

P-Selectin (CD62P)的概要

治療藥的開發

P-Selectin (CD62P):開發中的產品 - 各開發階段

P-Selectin (CD62P):開發中的產品 - 各治療範圍

P-Selectin (CD62P):開發中的產品 - 各適應症

P-Selectin (CD62P):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

P-Selectin (CD62P):企業開發中的產品

P-Selectin (CD62P):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

P-Selectin (CD62P)的治療藥的開發企業

  • Momenta Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Selexys Pharmaceuticals Corporation

藥物簡介

P-Selectin (CD62P):暫停中的計劃

P-Selectin (CD62P):開發中止的產品

P-Selectin (CD62P):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0136TDB

Summary

Global Markets Direct's, 'P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016', provides in depth analysis on P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted pipeline therapeutics.

The report provides comprehensive information on the P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)
  • The report reviews P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Overview
  • Therapeutics Development
    • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Stage of Development
    • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Therapy Area
    • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Indication
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Companies
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Companies Involved in Therapeutics Development
    • Momenta Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Selexys Pharmaceuticals Corporation
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Drug Profiles
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • necuparanib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rivipansel sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SelG-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Dormant Projects
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Discontinued Products
  • P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Featured News & Press Releases
    • Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
    • May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
    • Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
    • Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
    • Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
    • Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
    • Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
    • Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease
    • Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
    • May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
    • Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
    • Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease
    • Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting
    • Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
    • Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Selexys Pharmaceuticals Corporation, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top